Dear Psilothera, Inc. Investor,

Thank you for the generosity of your Support and Investment.

We thought it was essential to reach out to you and provide an update of the Company's activities and progress.

First, we have elected to change the name of the Corporation and are currently rebranding it as Enlightenment Mental Health, Inc. with many new and exciting changes including a new website soon at Enlightenment.Health.

Here are some of the highlights as we move forward as Enlightenment Mental Health, Inc.

• Our Platform Strategy:
  The platform strategy includes Mental Health Care Clinics and Centers, Tele-Mental Health Platform Development for Patient Therapist Sessions and M.D. visits, and Quantum Technology-based Psychedelic Drug Discovery.
• Areas of Practice Specializations:
  Psychotherapy, Suicide Intervention and Prevention, Psychedelic Administration, Cognitive Behavioral Therapy (CBT), Trauma Therapy, Brainspotting, Mindfulness, Meditation, Massage therapy, Yoga, Breathwork.
• Patient Focus:
  Treatment-Resistant Depression, Post-traumatic stress disorder (PTSD), Anxiety, Addiction, Eating Disorders, Suicide Intervention and Prevention, Mental Healthcare for Veterans, and 1st Responders.
• Psychedelic Focus:
  Our initial focus was on Psilocybin, but we are now concentrating on Ketamine since Ketamine is already legal and FDA-approved. This will position our clinics to transition immediately into MDMA, Psilocybin, Ayahuasca, and LSD as potential treatment options when they become FDA-approved and legalized.
• New Leadership:
  Joanne King, LMHC, has been recruited to be our new CEO and we believe her experience as an integrative mental health therapist and professional will help lead the company into a new era in psychedelic therapy innovation.
• Psychedelic Training Certification Programs:
  We have invested in training our therapists through the Integrated Psychiatry Institute for certification as a Psychedelic Assisted Therapy Provider. This certifies and allows our therapists to work directly with our clients who are using the medicine. The Psychedelic Training Certification includes Multidisciplinary Association for Psychedelic Studies (MAPS) Training, Ketamine, MDMA, and Psilocybin certification.
• Intellectual Property:
  We have filed a U.S. Patent for our Tele-Health Platform for Psychedelic Assisted Therapy.
• Mental Health Clinic Target Market Launch:
  There is a strong demand for Mental Healthcare Services, and we will first seek to open our clinics in Maui, Hawaii, and San Antonio, Texas, and Bend / Sisters, Oregon, which is the first state to grant Psilocybin licensing.
• Indigenous Cultural Guidance & Peru Retreat Joint Venture:
  Psychedelics have been used in Indigenous communities in therapeutic and religious settings for centuries, while psychedelic therapy is relatively new in Western clinical settings. We have partnered with K’uychi Florez Zevalloz and Luciano Florez Qquesihuallpa, Peruvian Shamans who have been healing people for many years through Ayahuasca. Our vision includes a Retreat Center in Cusco-Machu Picchu.
• Drug Discovery and Strategic Partners:
  We have formed some crucial relationships and entered into preliminary agreements with:
• • Polaris Q.B., a quantum technology discovery platform that also deploys A.I. and Machine Learning. We have researched psilocybin receptors for multiple indications and will start the discovery process when financially able to launch.
  • PsyRx, an Israeli-based Company with a Government License for Psychedelics and is working with Psilocybin and Ibogaine to create organic compounds.
• Psilocybin Production & Nutraceutical Strategic Partner:
  We have entered into an Agreement with a Canadian Company, Haven Life Biosciences, to provide Psilocybin and assist us with our planned Psilocybin grow. They have also agreed to provide us a Fungi and Brain Specialty Nutraceuticals via a white- label agreement.
• New Crowd Fund Round:
  We have signed an exciting deal with Broker-Dealer Deal Makers Securities to do our next $5 Million crowdfund round, and we expect to relaunch this effort over the next several weeks.
• Company Valuation – Providing You More Shares:
  We have elected to lower our Valuation significantly due to overall market conditions and the fact that most publicly traded Psychedelic sector companies have considerably reduced valuations.

  As such, we have reduced our Valuation from $50 Million to $25 Million and from $5.00 per share to $2.50 per share, for which we shall provide our Startengine.com investors with additional shares to reflect this change. Shares shall be added to the Company capitalization table in your designated name by the Deal Maker Securities Transfer Agent.